Farid Takes Helm of Aurion MAB - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Farid Takes Helm of Aurion MAB

Aurion Biotech names Marjan Farid chair of medical advisory board

  • March 27, 2026

  • 2 min

Share

Objective:

To announce the appointment of Marjan Farid as chair of Aurion Biotech's medical advisory board.

Approach:
    Key Findings:
    • Farid is recognized for her contributions to corneal and ocular surface disease.
    • Aurion's AURN001 aims to address progressive vision loss from corneal endothelial disease.
    • The company has launched Vyznova, the first commercially available cell therapy for corneal endothelial disease.
    Interpretation:

    Farid's expertise is expected to enhance Aurion's strategic initiatives and clinical advancements in regenerative therapies.

    Limitations:
    • The article does not provide detailed information on the specific roles and responsibilities Farid will undertake.
    • No data on the outcomes of AURN001's Phase 3 trials is included.
    Conclusion:

    Farid's leadership is anticipated to significantly influence the development of innovative treatments for corneal diseases.

    Sources:

Original Source(s)

Farid Takes Helm of Aurion MAB

  • March 27, 2026

Related Content

Smartphone Imaging System Supports Remote Cataract Screening

A low-cost smartphone imaging system could help expand cataract screening in rural and underserved communities.

  • September 11, 2026

  • 2 min
Study Tests IOL Durability in Space

Researchers evaluated how IOL materials held up after approximately 6 months outside the International Space Station.

  • September 11, 2026

  • 2 min
Myopia Patterns in Intermittent Exotropia

New findings indicate intermittent exotropia may influence binocular ocular growth patterns without significantly increasing myopia risk

  • July 15, 2026

  • 2 min